Digital Health Regulatory Affairs Services

Digital health is regulated based on the product's intended use, risk profile, claims, and functionality. Solutions that diagnose, monitor, or influence treatment may be regulated as medical devices, including Software as a Medical Device. Requirements often include classification analysis, technical documentation, risk management, software lifecycle controls, clinical evidence, cybersecurity considerations, and post-market obligations under authorities such as FDA, EU regulators, TGA, or Health Canada.

Regulatory affairs in healthcare involves guiding products through the rules that govern development, approval, market entry, labeling, quality systems, and post-market compliance. For digital health and medical devices, this includes pathway selection, submission planning, documentation review, authority interactions, standards alignment, and ongoing support to keep products compliant after launch in each target market.

SaMD stands for Software as a Medical Device, meaning software that performs a medical function without being part of a hardware medical device. In regulatory affairs, SaMD requires careful classification, intended use definition, software documentation, risk management, clinical or performance evidence, and alignment with standards such as IEC 62304 and ISO 14971. Regulatory expectations vary by market and device risk.

The best time to involve regulatory consultants is early, ideally before product claims, design inputs, testing plans, and market strategy are finalized. Early support helps avoid misclassification, weak evidence planning, and documentation gaps that can delay submissions later. Consultants can also help before pre-sub meetings, major design changes, market expansion, or responses to authority questions.

Common submission documents include device or software description, intended use, classification rationale, risk management file, software lifecycle documentation, verification and validation evidence, cybersecurity information, labeling, clinical or performance evidence, and quality system records. Depending on the market, teams may also need predicate comparisons, GSPR mapping, essential principles evidence, or post-market surveillance plans.

Yes. Elexes supports global regulatory strategies for companies targeting multiple markets, including the USA, Europe, Canada, Australia, the UK, and other regions. This includes pathway planning, documentation alignment, submission readiness, authority-specific requirements, and sequencing strategies that help companies manage timelines, evidence reuse, and compliance obligations across different jurisdictions more efficiently.

A submission readiness assessment identifies whether your product, documentation, evidence, and quality systems are truly prepared for regulatory review. It helps uncover missing test data, weak traceability, incomplete software records, labeling issues, or quality gaps before submission. That reduces the risk of deficiency letters, review delays, and costly rework while giving your team a prioritized remediation plan.

Yes. Approval or clearance is only one stage of compliance. Many digital health products require ongoing post-market support such as complaint handling, change impact assessments, reportability reviews, documentation updates, surveillance activities, and quality system maintenance. Software updates, cybersecurity changes, and evolving claims can all trigger regulatory review, making ongoing oversight important after market entry.